ConvaTec Group Plc stock (GB00BD3VFW73): growth push and dividend highlight medical technology ambitions

ConvaTec Group Plc is expanding its wound and ostomy care business while confirming a progressive dividend policy. Recent annual results and strategic updates show how the medtech group wants to accelerate growth and improve margins in the coming years.

ConvaTec Group Plc is a specialist in medical products such as advanced wound dressings and ostomy care supplies. The company recently presented its latest annual figures and updated its strategy, underlining ambitions for faster growth and higher profitability in key therapy areas, according to the company’s full-year 2024 results release published on March 7, 2025 on its website (ConvaTec press release as of 03/07/2025). For US-focused investors, the stock offers exposure to demand for chronic care solutions in both North America and Europe.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ConvaTec
• Sector/industry: Medical technology, chronic care products
• Headquarters/country: Reading, United Kingdom
• Core markets: Europe, North America and other international healthcare markets
• Key revenue drivers: Advanced wound care, ostomy care, continence and critical care, infusion care
• Home exchange/listing venue: London Stock Exchange (ticker: CTEC)
• Trading currency: GBX (Pence sterling)

ConvaTec Group Plc: core business model

ConvaTec Group Plc focuses on products for patients who require long-term treatment in areas such as wound care, ostomy care and continence management. In its full-year 2024 report, the group described itself as a provider of chronic care solutions with a strong presence in hospitals, home care and community settings, according to company disclosures dated March 7, 2025 (ConvaTec press release as of 03/07/2025). The business is organized into divisions that each serve specific clinical needs and reimbursement structures.

The advanced wound care unit supplies dressings and related technologies for chronic and acute wounds, addressing a growing population of patients with diabetes, vascular disease and pressure ulcers. Ostomy care products are aimed at people who have undergone surgery resulting in a stoma, requiring reliable appliances and accessories for daily life. Continence and critical care offerings include catheters and urine management systems used both in hospitals and at home, while the infusion care division develops infusion sets that are used with insulin pumps and other therapies.

The company’s revenue model is primarily based on repeat purchases of consumable products that are prescribed by physicians and reimbursed by healthcare payers. This recurring nature of demand can create relatively stable cash flows over time, though pricing and reimbursement decisions by public and private insurers remain a key external factor. ConvaTec highlights in its annual report that it aims to differentiate through specialized sales forces, clinical support and product innovation, according to its 2024 annual results documentation published in March 2025 (ConvaTec press release as of 03/07/2025).

Main revenue and product drivers for ConvaTec Group Plc

In its full-year 2024 results, ConvaTec reported that group revenue grew on an organic basis compared with the prior year, driven in particular by advanced wound care and infusion care, according to the press release on March 7, 2025 (ConvaTec press release as of 03/07/2025). Management pointed to increased adoption of advanced dressings and strong momentum in infusion sets used for diabetes therapy as important contributors. The company also emphasized solid demand in ostomy care, although growth rates varied across regions.

Advanced wound care is structurally supported by aging populations and rising incidence of chronic conditions, especially in developed healthcare systems. ConvaTec’s portfolio includes foam dressings, antimicrobial products and other specialized solutions that aim to support healing and reduce complications. In the US market, hospitals and outpatient clinics represent an important sales channel, with purchasing decisions often influenced by guidelines, clinical evidence and cost-effectiveness benchmarks. In its report, the company highlighted new product launches and extended indications in wound care as priorities for sustaining growth over the coming years, according to its 2024 results communication of March 2025 (ConvaTec press release as of 03/07/2025).

Ostomy care is another key pillar, benefiting from the need for reliable, comfortable devices that patients use daily. ConvaTec competes with other global medtech companies in this segment and seeks to differentiate through product design, skin protection technologies and support services that help patients adjust after surgery. Because ostomy products are used every day and replaced regularly, retention of customers and relationships with healthcare professionals can be decisive for long-term revenue. The company has indicated that investments in digital tools and patient engagement programs are intended to strengthen loyalty in this segment, as described in its strategic update for 2024 published in March 2025 (ConvaTec press release as of 03/07/2025).

Infusion care, which includes infusion sets for insulin pumps used by people with diabetes, has also become a growth engine. The division benefits from rising use of insulin pumps and continuous glucose monitoring systems across the US and Europe. The company noted in its 2024 results that this segment delivered strong growth supported by existing OEM partnerships and new agreements with device manufacturers, according to the same March 7, 2025 announcement on its website (ConvaTec press release as of 03/07/2025). Continued innovation, product reliability and regulatory compliance are central factors for sustaining this contribution.

In addition to segment growth, ConvaTec is working on improving operating margins through a mix of cost efficiencies, supply chain optimization and portfolio prioritization. The company’s 2024 results press release highlighted progress under its multi-year margin improvement initiatives, mentioning adjusted operating margin expansion versus the prior year, as reported on March 7, 2025 (ConvaTec press release as of 03/07/2025). For investors, this combination of mid-single-digit to higher organic growth ambitions and margin improvement targets plays a central role in equity valuation discussions.

Why ConvaTec Group Plc matters for US investors

Although ConvaTec is listed on the London Stock Exchange, the company generates a significant portion of its sales in North America. In the 2024 results presentation, management highlighted the importance of the US market for advanced wound care and infusion care, where clinical practice and reimbursement frameworks often shape global standards, according to its March 7, 2025 disclosures on the company website (ConvaTec press release as of 03/07/2025). For US-based investors, the stock therefore offers indirect participation in American healthcare trends, even though it trades in London in pence sterling.

Key themes that influence ConvaTec’s outlook include demographic change, the prevalence of chronic diseases such as diabetes and vascular problems, and efforts to manage healthcare costs by avoiding complications and hospital readmissions. Technologies that support wound healing, reduce infection risk or simplify chronic disease management can be attractive to health systems trying to balance quality and cost. ConvaTec’s focus on chronic care means its portfolio is closely tied to these long-term structural developments, as described in its annual report for 2024 published in March 2025 (ConvaTec press release as of 03/07/2025).

Currency exposure is another consideration. Because the shares are quoted in pounds sterling while a part of the revenue base is in US dollars and other currencies, movements in exchange rates can influence reported earnings and the value of dividends in US dollar terms. The company notes currency impacts on revenue and profit in its financial commentary, and investors who calculate performance in dollars will also see translation effects in portfolio valuations, according to the full-year 2024 financial statements discussed in March 2025 (ConvaTec press release as of 03/07/2025).

For US investors following the global medtech space, ConvaTec can also serve as a diversification element alongside large US-listed peers. Its focus on chronic care consumables, rather than capital equipment, gives it a slightly different risk and demand profile compared with companies that depend more heavily on one-off device sales. The recurring nature of product usage in ostomy, continence and wound care means that demand is closely linked to patient numbers and treatment patterns. However, competition, regulatory requirements and reimbursement decisions in the US market remain central variables that can influence future growth and profitability, as highlighted in the 2024 results commentary from March 7, 2025 (ConvaTec press release as of 03/07/2025).

Conclusion

ConvaTec Group Plc is positioning itself as a focused chronic care specialist with ambitions to accelerate organic growth and improve margins after its full-year 2024 results, as summarized in its March 7, 2025 release (ConvaTec press release as of 03/07/2025). The main revenue engines remain advanced wound care, ostomy care and infusion care, each benefiting from structural healthcare trends but also facing competition and regulatory complexity. For US-focused investors, the London-listed stock offers exposure to chronic care demand in North America and Europe, combined with the particular opportunities and risks of a mid-sized global medtech company operating in multiple currencies.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.